Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2008

01-03-2008 | Image of the month

Discrepancy between glucose metabolism and sympathetic nerve terminals in a patient with metastatic paraganglioma

Authors: Kambiz Rahbar, Peter Kies, Lars Stegger, Kai Uwe Juergens, Matthias Weckesser

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2008

Login to get access

Excerpt

There are several radiotracers currently available for detecting tumors of the sympathetic nervous system. [123I]-meta-iodobenzylguanidine (MIBG) is commonly used with planar imaging and single photon emission computerised tomography (SPECT) and depicts presynaptic noradrenalin reuptake. Alternatively, the positron emitting radiopharmaceutical [11C]-meta-hydroxyephedrine (mHED) may be used together with positron emission tomography (PET) to measure the same molecular process; the superior imaging characteristics may allow to detect tumours with a higher sensitivity compared to MIBG-SPECT [1]. …
Literature
1.
Franzius C, Hermann K, Weckesser M, Kopka K, Juergens KU, Vormoor J, et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med 2006;47:1635–42.PubMed
2.
Mamede M, Carrasquillo JA, Chen CC, Del Corral P, Whatley M, Ilias I, et al. Discordant localization of 2-[18F]-fluoro-2-deoxy-d-glucose in 6-[18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 2006;27:31–6.PubMedCrossRef
Metadata
Title
Discrepancy between glucose metabolism and sympathetic nerve terminals in a patient with metastatic paraganglioma
Authors
Kambiz Rahbar
Peter Kies
Lars Stegger
Kai Uwe Juergens
Matthias Weckesser
Publication date
01-03-2008
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-007-0646-4

Other articles of this Issue 3/2008

European Journal of Nuclear Medicine and Molecular Imaging 3/2008 Go to the issue

EDITORIAL COMMENTARY

Can cardiac iodine-123 metaiodobenzylguanidine imaging contribute to risk stratification in heart failure patients?

Short Communication

Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer

Image of the month

FDG PET/CT findings in primary hyperparathyroidism mimicking multiple bone metastases

Controversy

EANM–ESR white paper on multimodality imaging

Original Article

Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET

Focus on...

Cardiac sympathetic denervation imaging in movement disorders and dementias